[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100618594":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":41,"responsibleParty":56,"collaborators":25,"id":60,"slug":25,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":25,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":25,"enrollmentInfo":68,"targetDuration":25,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":82,"whyStopped":25,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Jinan Military General Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard of Care (SOC)","ACTIVE_COMPARATOR","Participants receive standard-of-care systemic anticancer therapy per treating physician discretion, which may include chemotherapy, immunotherapy, targeted therapy, and\u002For maintenance therapy according to current clinical guidelines and individual molecular profiles.",[13],"Other: Standard-of-Care Systemic Therapy",{"label":15,"type":16,"description":17,"interventionNames":18},"125I Seed Implantation plus Standard of Care","EXPERIMENTAL","Participants undergo image-guided 125I seed implantation to all extracranial oligoprogressive lesions, followed by continuation of standard-of-care systemic anticancer therapy as determined by the treating physician.",[13,19],"Procedure: 125I Seed Implantation",[21,26],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"Standard-of-Care Systemic Therapy","Standard systemic anticancer therapy administered according to current clinical guidelines and treating physician discretion, which may include chemotherapy, immunotherapy, targeted therapy, and\u002For maintenance therapy.",[15,9],null,{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":25},"PROCEDURE","125I Seed Implantation","Image-guided implantation of iodine-125 (125I) radioactive seeds to all extracranial oligoprogressive lesions for local tumor control, performed under CT or PET\u002FCT guidance according to institutional standards.",[15],[32],{"name":33,"affiliation":34,"role":35},"Min Li, M.D.","The 960th Hospital of People's Liberation Army (PLA)","STUDY_DIRECTOR",[37],{"name":33,"role":38,"phone":39,"phoneExt":25,"email":40},"CONTACT","0531-51665482","liminyingxiang.@163.com",[42],{"facility":34,"status":25,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Jinan","Shandong","250031","China","CN",{"type":49,"coordinates":50},"Point",[51,52],116.99722,36.66833,{"lat":52,"lon":51},[55],{"name":33,"role":38,"phone":39,"phoneExt":25,"email":40},{"type":57,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"SPONSOR_INVESTIGATOR","Li Min","Vice Director","100618594",false,"NCT07333651","125I Seed Implantation Plus Systemic Therapy for Oligoprogressive NSCLC or Colorectal Cancer","Standard-of-Care Systemic Therapy With or Without Image-Guided 125I Seed Implantation in Patients With Oligoprogressive Metastatic Non-Small Cell Lung Cancer or Colorectal Cancer: An Open-Label, Randomized, Controlled Phase 2 Study","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Histologically or cytologically confirmed metastatic non-small cell lung cancer (NSCLC) or colorectal cancer (CRC).\n* Presence of metastatic disease with extracranial oligoprogression, defined as progression in up to five (≤5) individual lesions on CT or PET\u002FCT imaging, while other known disease sites remain stable or controlled.\n* Received at least one prior line of standard systemic anticancer therapy, including maintenance therapy, for metastatic disease.\n* All oligoprogressive lesions are technically feasible and considered safe for image-guided 125I seed implantation, as determined by the treating interventional team.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Adequate organ function to undergo interventional procedures and systemic therapy, per institutional standards.\n* Ability to understand and willingness to sign written informed consent.\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding.\n* Leptomeningeal disease or diffuse central nervous system involvement. Uncontrolled infection or serious medical comorbidities that, in the investigator's judgment, would preclude safe participation or interventional procedures.\n* Prior radiotherapy or brachytherapy requiring re-irradiation to the same tumor location planned for 125I seed implantation.\n* Known bleeding diathesis or uncorrectable coagulation disorders contraindicating interventional procedures.\n* Any other condition that, in the investigator's judgment, would make the patient unsuitable for the study.","ALL","18 Years",{"count":69,"type":70},90,"ESTIMATED","INTERVENTIONAL",[73],"PHASE2","Most patients with metastatic cancer eventually develop resistance to systemic therapy. A subset of patients experience oligoprogression, characterized by progression at a limited number of lesions while other disease sites remain controlled by ongoing systemic therapy. This randomized phase 2 trial evaluates whether image-guided 125I seed implantation targeting all oligoprogressive extracranial lesions, combined with standard-of-care systemic therapy, improves progression-free survival compared with standard-of-care systemic therapy alone in patients with metastatic NSCLC or CRC.",[76],"Oligometastatic Disease",[78,79,80,81],"lodine-125 Seed Brachytherapy","Oligoprogression","Non-Small Cell Lung Cancer","Colorectal Cancer","NOT_YET_RECRUITING","2026-01-02",{"date":85,"type":86},"2026-01-12","ACTUAL",{"date":88,"type":70},"2026-01",{"date":90,"type":70},"2028-01-01",{"name":58,"class":6},1]